Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Illumina, Inc. of $750 million aggregate principal amount of its 0.0% convertible senior notes due 2023, which includes the full exercise of the initial purchasers’ option to purchase additional notes.

Based in San Diego, California, Illumina is the global leader in sequencing- and array-based solutions for genetic analysis. Its products and services serve customers in a wide range of markets, enabling the adoption of genomic solutions in research and clinical settings. Illumina’s common stock is listed on the NASDAQ Global Select Market under the symbol “ILMN.”

The Davis Polk corporate team included partner Derek Dostal and associates Matthew M. Funk and Grecia Barboza. The equity derivatives team included partners Mark M. Mendez and Mark J. DiFiore and associate Won Lee. The tax team included partner Lucy W. Farr. Partner Pritesh P. Shah and associate Yifu Chen provided intellectual property and technology advice. Counsel Loyti Cheng provided environmental advice. All members of the Davis Polk team are based in the New York Office.

 

Copy link to share post